Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: results from the epicovideha registry

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013594" target="_blank" >RIV/00023736:_____/24:00013594 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/24:00135446 RIV/61989592:15110/24:73620812 RIV/65269705:_____/24:00079122 RIV/00179906:_____/24:10481283 and 2 more
Result on the web
<a href="https://doi.org/10.1002/hon.3240" target="_blank" >https://doi.org/10.1002/hon.3240</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/hon.3240" target="_blank" >10.1002/hon.3240</a>

Result language
angličtina
Original language name
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: results from the epicovideha registry
Original language description
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)